Predictive Biomarkers of Response to Venetoclax in Combination with Cobimetinib in Relapsed/Refractory Multiple Myeloma (RRMM)
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-134910
Abstract: Introduction: Both anti-apoptosis and pro-survival mechanisms promote myeloma cell growth and proliferation, and B-cell lymphoma-2 (BCL-2) is over-expressed in a subset of myeloma patients (pts). Venetoclax (V; orally administered BCL-2 inhibitor) monotherapy has demonstrated efficacy… read more here.
Keywords: kras braf; combination; nras kras; response ... See more keywords
Contrasting Clinical Implications of NRAS Vs. KRAS Mutations in AML - Only KRAS Mutations Are Associated with Adverse Outcome
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-202833
Abstract: Introduction: Acute myeloid leukemia (AML) is a genetically and clinically heterogenous malignancy with highly prevalent structural alterations and less common sequence variants in children and adolescents. NRAS and KRAS mutations are the most prevalent mutations… read more here.
Keywords: risk; nras kras; kmt2a aml; g12 g13 ... See more keywords
IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Translational Medicine"
DOI: 10.1186/s12967-024-05384-4
Abstract: Oncogenic mutations in the RAS gene are associated with uncontrolled cell growth, a hallmark feature contributing to tumorigenesis. While diverse therapeutic strategies have been diligently applied to treat RAS-mutant cancers, successful targeting of the RAS… read more here.
Keywords: treatment; nras kras; culture; inhibitor ... See more keywords